Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Long-Term Investments (2021 - 2026)

Protara Therapeutics' Long-Term Investments history spans 5 years, with the latest figure at $41.6 million for Q1 2026.

  • Quarterly Long-Term Investments rose 25.6% to $41.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $41.6 million through Mar 2026, up 25.6% year-over-year, with the annual reading at $42.3 million for FY2025, N/A changed from the prior year.
  • Long-Term Investments came in at $41.6 million for Q1 2026, down from $42.3 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $42.3 million in Q4 2025 to a low of $957000.0 in Q3 2025.
  • The 4-year median for Long-Term Investments is $20.6 million (2022), against an average of $21.8 million.
  • Year-over-year, Long-Term Investments tumbled 90.63% in 2023 and then rose 25.6% in 2026.
  • Protara Therapeutics' Long-Term Investments stood at $17.9 million in 2022, then plummeted by 83.83% to $2.9 million in 2023, then surged by 1363.39% to $42.3 million in 2025, then dropped by 1.64% to $41.6 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Long-Term Investments are $41.6 million (Q1 2026), $42.3 million (Q4 2025), and $957000.0 (Q3 2025).